

RESEARCH REPORT



LIQUID BIOPSY MARKETS
BY CANCER, USAGE, BIOMARKER, PLACE, & PRODUCT
WITH PRICE AND VOLUME OUTLOOK.
INCLUDING EXECUTIVE AND CONSULTANT GUIDES AND
CUSTOMIZED FORECASTING AND ANALYSIS
2023 - 2027



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- 1 Market Guides26
 - 1.1 Liquid Biopsy Market - Strategic Situation Analysis 27
 - 1.2 Guide for Executives, Marketing, Sales and Business Development Staff 29
 - 1.3 Guide for Management Consultants and Investment Advisors..... 31
- 2 Introduction and Market Definition32
 - 2.1 What is Liquid Biopsy? 33
 - 2.2 The Sequencing Revolution 34
 - 2.3 Market Definition 36
 - 2.3.1 Revenue Market Size 36
 - 2.4 Methodology..... 38
 - 2.4.1 Methodology 38
 - 2.4.2 Sources 38
 - 2.4.3 Authors 38
 - 2.5 Perspective: Healthcare and the IVD Industry 40
 - 2.5.1 Global Healthcare Spending 40
 - 2.5.2 Spending on Diagnostics 42
 - 2.5.3 Important Role of Insurance for Diagnostics 43
- 3 Market Overview.....44
 - 3.1 Players in a Dynamic Market..... 45

- 3.1.1 Academic Research Lab 46
- 3.1.2 Diagnostic Test Developer..... 47
- 3.1.3 Instrumentation Supplier 47
- 3.1.4 Chemical/Reagent Supplier..... 47
- 3.1.5 Pathology Supplier 48
- 3.1.6 Independent Clinical Laboratory 48
- 3.1.7 Public National/regional Laboratory 48
- 3.1.8 Hospital Laboratory 49
- 3.1.9 Physicians Office Lab (POLs) 49
- 3.1.10 Audit Body 50
- 3.1.11 Certification Body..... 50
- 3.2 Using Biopsies..... 52
 - 3.2.1 Cancer 52
 - 3.2.2 Precancerous conditions..... 53
 - 3.2.3 Inflammatory conditions..... 53
- 3.3 Biopsy Sites..... 54
- 3.4 The Situation Today – Biopsy Analysis 56
- 3.5 Evidence of Cancer - Liquid Biopsy Technology..... 57
 - 3.5.1 The Big Picture on Liquid Biopsy Technology 57
 - 3.5.2 The Role of CTCs..... 60
 - 3.5.3 Application of CTCs 61
 - 3.5.4 CellSearch Detection- Ultimate Sensitivity 62
 - 3.5.5 Epic Sciences Detection- Imaging Takes the Lead..... 63
 - 3.5.6 Maintrac Detection – The Microscope..... 64

- 3.5.7 Other Methods 66
- 3.5.8 ctDNA Role 67
- 3.5.9 ctDNA Applications..... 68
- 3.5.10 Exosomes and Micro Vesicles – New Kid on the Block..... 70
- 3.5.11 The Multiple Play..... 73
- 3.6 Cancer Treatment Protocol Under Siege..... 75
 - 3.6.1 Issues to Liquid Biopsy Adoption – Double Diagnostics..... 76
 - 3.6.2 The Cancer Screening Market Opportunity..... 77
 - 3.6.2.1 GRAIL – What Is It? 78
 - 3.6.3 Cancer Management vs. Diagnosis..... 79
 - 3.6.3.1 The Role of Risk Assessment 79
 - 3.6.3.2 Managing Therapy 80
 - 3.6.3.3 Monitoring Disease – What Is It? 80
 - 3.6.4 Phases of Adoption – Looking into The Future 81
 - 3.6.5 The Promise of Liquid Biopsy 82
- 3.7 Structure of Industry Plays a Part..... 84
 - 3.7.1 Hospital Testing Share 84
 - 3.7.2 Economies of Scale..... 84
 - 3.7.2.1 Hospital vs. Central Lab..... 85
 - 3.7.3 Physician Office Lab's..... 86
 - 3.7.4 Physician's and POCT 86
- 4 Market Trends88
 - 4.1 Factors Driving Growth 89
 - 4.1.1 Non-Invasive Game Changer..... 89

- 4.1.2 Lower Cost 90
- 4.1.3 Greater Accuracy 90
- 4.1.4 Wide Range of Potential Uses 90
- 4.1.5 Aging Population..... 91
- 4.2 Factors Limiting Growth 94
 - 4.2.1 Lower prices..... 94
 - 4.2.2 Lack of Standards 95
 - 4.2.3 Protocol Resistance..... 95
 - 4.2.4 Initial Adoption Cost..... 95
 - 4.2.5 Conclusion 95
- 4.3 Instrumentation and Automation 96
 - 4.3.1 Instruments Key to Market Share 96
 - 4.3.2 Bioinformatics Plays a Role 96
- 4.4 Diagnostic Technology Development 97
 - 4.4.1 Next Generation Sequencing Fuels a Revolution..... 98
 - 4.4.2 Impact of NGS on pricing..... 99
 - 4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment..... 99
 - 4.4.4 CGES Testing, A Brave New World 100
 - 4.4.5 Biochips/Giant magneto resistance based assay..... 100
- 5 Liquid Biopsy Recent Developments 102
 - 5.1 Recent Developments – Importance and How to Use This Section 103
 - 5.1.1 Importance of These Developments 103
 - 5.1.2 How to Use This Section..... 103
 - 5.2 Sophia Genetics to Commercialize Liquid Biopsy Test..... 103

5.3 Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx..... 104

5.4 Liquid Biopsy Startup Haystack Oncology Raises \$56M..... 105

5.5 Hedera Dx to Launch Liquid Biopsy Streamlined Platform 106

5.6 PamGene Expanding Liquid Biopsy Assays 108

5.7 Liquid Biopsy Firm Hedera Dx Raises €14M..... 110

5.8 MDxHealth Plans One-Stop Shop for Prostate Cancer Dx..... 111

5.9 Precision Oncology Dx Access Varies Widely in Europe..... 113

5.10 Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic..... 117

5.11 Predicine Receives CE Mark for Blood and Urine Liquid Biopsy 121

5.12 BillionToOne Launches First Liquid Biopsy Products 121

5.13 Dxcover Advances Multicancer Detection Platform..... 122

5.14 CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test . 124

5.15 Illumina Sues Guardant Health Over Patents..... 125

5.16 Invitae to Expand Cancer Testing Portfolio..... 128

5.17 Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies..... 132

5.18 IVBH Bio Takes Aim at With Liquid Biopsy Incubator..... 133

5.19 Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership 136

5.20 Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech 136

5.21 BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy 139

5.22 EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform..... 142

5.23 Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding..... 145

5.24 Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition..... 146

5.25 Bio-Techne to Acquire Asuragen for up to \$320M 150

5.26 Personalis Broadens Liquid Biopsy Offering 151

5.27	Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition.....	153
5.28	Delfi Diagnostics Plans Multi-Cancer Screening Test.....	156
5.29	Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response.....	157
5.30	Liquid Biopsy NGS Panels - Diverse Test Claims.....	160
5.31	CMS Colon Cancer Screening Memo Bodes Well for Assays.....	166
5.32	Natera Liquid Biopsy Test Coverage to Expand.....	168
5.33	Freenome Closes Financing to Support Early Cancer Detection Trial.....	169
5.34	C\$2.6M Liquid Biopsy Initiative.....	170
5.35	NeoGenomics, Invata Partner for Lung Cancer Liquid Biopsy.....	171
5.36	Liquid Biopsy Shows Promise as Screen for Cancers.....	172
5.37	Invata launches RaDaR™ for the detection of residual disease and recurrence...	173
5.38	Liquid Biopsy Assay Detects 50+ Types of Cancer.....	174
5.39	Liquid Biopsy Study Confirms Concordance with Tissue Biopsy.....	176
6	Profiles of Key Players.....	179
6.1	Abbott Laboratories.....	180
6.2	AccuraGen Inc.	182
6.3	Acuamark Diagnostics.....	183
6.4	Admera Health, LLC.....	184
6.5	Agilent/Dako.....	186
6.6	Amoy Diagnostics Co., Ltd.....	189
6.7	Anchor Dx.....	190
6.8	ANGLE plc.....	192
6.9	Applied DNA Sciences.....	193

6.10	ARUP Laboratories.....	195
6.11	AVIVA Systems Biology.....	197
6.12	Baylor Miraca Genetics Laboratories.....	198
6.13	Beckman Coulter Diagnostics.....	199
6.14	Becton, Dickinson and Company	201
6.15	BGI Genomics Co. Ltd	203
6.16	Bioarray Genetics.....	205
6.17	Biocartis.....	206
6.18	Biocept, Inc.....	208
6.19	Biodesix Inc.	210
6.20	BioFluidica.....	211
6.21	bioMérieux Diagnostics.....	212
6.22	Bioneer Corporation	215
6.23	Bio-Rad Laboratories, Inc.....	217
6.24	Bio-Techne	220
6.25	Bioview	222
6.26	Bolidics	224
6.27	Boreal Genomics.....	226
6.28	Burning Rock.....	227
6.29	Cardiff Oncology	229
6.30	Caris Molecular Diagnostics	230
6.31	CellCarta	231
6.32	CellMax Life	233
6.33	Cepheid (Danaher)	234

6.34	Circulogene.....	236
6.35	Cizzle Biotech.....	237
6.36	Clinical Genomics.....	238
6.37	Cytolumina Technologies Corp.....	239
6.38	Datar Cancer Genetics Limited.....	240
6.39	Diagnologix LLC.....	241
6.40	Dxcover.....	242
6.41	Enzo Biochem.....	243
6.42	Epic Sciences.....	245
6.43	Epigenomics AG.....	246
6.44	Eurofins Scientific.....	247
6.45	Exact Sciences.....	250
6.46	Fluxion Biosciences.....	252
6.47	Freenome.....	253
6.48	Fyr Diagnostics.....	254
6.49	GeneFirst Ltd.....	256
6.50	Genetron Holdings.....	257
6.51	GILUPI Nanomedizin.....	259
6.52	Guardant Health.....	260
6.53	HansaBiomed.....	261
6.54	Haystack Oncology.....	262
6.55	HeiScreen.....	263
6.56	Helomics.....	265
6.57	iCellate.....	267

6.58	ICON PLC	268
6.59	Illumina	270
6.60	Incell Dx.....	272
6.61	Inivata	273
6.62	INOVIQ	274
6.63	Integrated Diagnostics	275
6.64	Invitae Corporation.....	276
6.65	Janssen Diagnostics	277
6.66	Lunglife AI Inc	278
6.67	MDNA Life SCIENCES, Inc.....	279
6.68	MDx Health	280
6.69	Menarini Silicon Biosystems.....	282
6.70	Mesa Laboratories, Inc.	283
6.71	Millipore Sigma	285
6.72	Miltenyi Biotec	286
6.73	miR Scientific.....	287
6.74	Myriad Genetics/Myriad RBM	288
6.75	NantHealth, Inc.	290
6.76	Natera	292
6.77	NeoGenomics	294
6.78	Novogene Bioinformatics Technology Co., Ltd.....	296
6.79	On-Chip Biotechnologies	298
6.80	Oncocyte.....	300
6.81	OncoDNA	301

6.82	Oxford Nanopore Technologies	302
6.83	PamGene	304
6.84	Panagene.....	305
6.85	Perkin Elmer.....	306
6.86	Personal Genome Diagnostics.....	308
6.87	Precision Medicine Group	309
6.88	PrecisionMed.....	310
6.89	Predicine	311
6.90	Promega	312
6.91	Qiagen.....	314
6.92	Rarecells SAS.....	317
6.93	RareCyte.....	318
6.94	Roche Molecular Diagnostics	319
6.95	ScreenCell	321
6.96	Siemens Healthineers	322
6.97	simfo GmbH.....	324
6.98	Singlera Genomics Inc.....	325
6.99	Standard BioTools	326
6.100	Sysmex Inostics.....	328
6.101	Tempus Labs, Inc.	330
6.102	Thermo Fisher Scientific Inc.....	331
6.103	Todos Medical	334
6.104	Veracyte	335
6.105	Volition	336

6.106 Vortex Biosciences 337

7 The Global Market for Liquid Biopsy Diagnostics338

7.1 Global Market Overview by Country 339

7.1.1 Table – Global Market by Country..... 339

7.1.2 Chart - Global Market by Country..... 340

7.2 Global Market by Cancer - Overview..... 341

7.2.1 Table – Global Market by Cancer 341

7.2.2 Chart – Global Market by Cancer – Base/Final Year Comparison 342

7.2.3 Chart – Global Market by Cancer – Base Year 343

7.2.4 Chart – Global Market by Cancer – End Year..... 344

7.2.5 Chart – Global Market by Cancer – Share by Year 345

7.2.6 Chart – Global Market by Cancer – Segments Growth..... 346

7.3 Global Market by Usage - Overview 347

7.3.1 Table – Global Market by Usage..... 347

7.3.2 Chart – Global Market by Usage – Base/Final Year Comparison 348

7.3.3 Chart – Global Market by Usage – Base Year..... 349

7.3.4 Chart – Global Market by Usage – End Year 350

7.3.5 Chart – Global Market by Usage – Share by Year..... 351

7.3.6 Chart – Global Market by Usage – Segments Growth..... 352

7.4 Global Market by Place - Overview 353

7.4.1 Table – Global Market by Place..... 353

7.4.2 Chart – Global Market by Place – Base/Final Year Comparison 354

7.4.3 Chart – Global Market by Place – Base Year..... 355

7.4.4 Chart – Global Market by Place – End Year 356

- 7.4.5 Chart – Global Market by Place – Share by Year..... 357
- 7.4.6 Chart – Global Market by Place – Segments Growth..... 358
- 7.5 Global Market by Marker - Overview..... 359
 - 7.5.1 Table – Global Market by Marker 359
 - 7.5.2 Chart – Global Market by Marker – Base/Final Year Comparison 360
 - 7.5.3 Chart – Global Market by Marker – Base Year 361
 - 7.5.4 Chart – Global Market by Marker – End Year 362
 - 7.5.5 Chart – Global Market by Marker – Share by Year..... 363
 - 7.5.6 Chart – Global Market by Marker – Segments Growth..... 364
- 7.6 Global Market by Product - Overview 365
 - 7.6.1 Table – Global Market by Product..... 365
 - 7.6.2 Chart – Global Market by Product – Base/Final Year Comparison..... 366
 - 7.6.3 Chart – Global Market by Product – Base Year..... 367
 - 7.6.4 Chart – Global Market by Product – End Year 368
 - 7.6.5 Chart – Global Market by Product – Share by Year..... 369
 - 7.6.6 Chart – Global Market by Product – Segments Growth 370
- 8 Global Liquid Biopsy Diagnostic Markets – By Cancer.....371
 - 8.1 Breast 372
 - 8.1.1 Table Breast – by Country..... 372
 - 8.1.2 Table Breast – by Country, Price..... 373
 - 8.1.3 Table Breast – by Country Volume..... 374
 - 8.1.4 Chart - Breast Growth 375
 - 8.2 Colorectal..... 376
 - 8.2.1 Table Colorectal – by Country 376

- 8.2.2 Table Colorectal – by Country, Price..... 377
- 8.2.3 Table Colorectal – by Country, Volume..... 378
- 8.2.4 Chart - Colorectal Growth..... 379
- 8.3 Cervical..... 380
 - 8.3.1 Table Cervical – by Country 380
 - 8.3.2 Table Cervical – by Country, Price..... 381
 - 8.3.3 Table Cervical – by Country, Volume..... 382
 - 8.3.4 Chart - Cervical Growth 383
- 8.4 Lung..... 383
 - 8.4.1 Table Lung – by Country 384
 - 8.4.2 Table Lung – by Country, Price..... 385
 - 8.4.3 Table Lung – by Country, Volume..... 386
 - 8.4.4 Chart - Lung Growth 387
- 8.5 Prostate..... 388
 - 8.5.1 Table Prostate – by Country 388
 - 8.5.2 Table Prostate – by Country, Price 389
 - 8.5.3 Table Prostate – by Country, Volume 390
 - 8.5.4 Chart – Prostate Growth 391
- 8.6 Other 392
 - 8.6.1 Table Other – by Country 392
 - 8.6.2 Table Other – by Country, Price 393
 - 8.6.3 Table Other – by Country, Volume 394
 - 8.6.4 Chart - Other Growth..... 395
- 9 Global Liquid Biopsy Diagnostic Markets – by Usage.....396

- 9.1 Screening..... 397
 - 9.1.1 Table Screening – by Country 397
- 9.2 Chart - Screening Growth 398
- 9.3 Diagnostic..... 399
 - 9.3.1 Table Diagnostic – by Country 399
 - 9.3.2 Chart - Diagnostic Growth..... 400
- 9.4 Therapy 401
 - 9.4.1 Table Therapy – by Country..... 401
 - 9.4.2 Chart - Therapy Growth 402
- 9.5 Monitor..... 403
 - 9.5.1 Table Monitor – by Country 403
 - 9.5.2 Chart - Monitor Growth..... 404
- 10 Global Liquid Biopsy Diagnostic Markets – by Place 405
 - 10.1 Hospital Lab 406
 - 10.1.1 Table Hospital Lab – by Country 406
 - 10.1.2 Chart - Hospital Lab Growth..... 407
 - 10.2 Lab Service 408
 - 10.2.1 Table Lab Service – by Country 408
 - 10.2.2 Chart - Lab Service Growth..... 409
 - 10.3 Lab Outpatient..... 410
 - 10.3.1 Table Lab Outpatient – by Country 410
 - 10.3.2 Chart - Lab Outpatient Growth 411
 - 10.4 Other Lab..... 412
 - 10.4.1 Table Other Lab – by Country 412

- 10.4.2 Chart - Other Lab Growth 413
- 11 Global Liquid Biopsy Diagnostic Markets – by Marker414
 - 11.1 Circulating Tumor Cell..... 415
 - 11.1.1 Table Circulating Tumor Cell – by Country..... 415
 - 11.1.2 Chart - Circulating Tumor Cell Growth 416
 - 11.2 Cell Free DNA 417
 - 11.2.1 Table Cell Free DNA – by Country..... 417
 - 11.2.2 Chart - Cell Free DNA Growth..... 418
 - 11.3 Vesicle 419
 - 11.3.1 Table Vesicle – by Country 419
 - 11.3.2 Chart - Vesicle Growth..... 420
 - 11.4 Other Marker 421
 - 11.4.1 Table Other Marker – by Country..... 421
 - 11.4.2 Chart - Other Marker Growth 422
- 12 Global Liquid Biopsy Diagnostic Markets – by Product.....423
 - 12.1 Kits..... 424
 - 12.1.1 Table Kits – by Country 424
 - 12.1.2 Chart - Kits Growth 425
 - 12.2 Instruments..... 426
 - 12.2.1 Table Instruments – by Country 426
 - 12.2.2 Chart - Instruments Growth..... 427
 - 12.3 Service..... 428
 - 12.3.1 Table Service – by Country 428
 - 12.3.2 Chart - Service Growth 429

13 Appendices.....430

13.1 United States Medicare System: 2022 Clinical Laboratory Fees Schedule..... 430

Table of Tables

Table 1 Market Players by Type 46

Table 2 Biopsy Sites 54

Table 3 LB Clinical Applications by Entity 75

Table 4 Advantages of Liquid Biopsy in Screening Market 78

Table 5 Outlook - Phases of Liquid Biopsy Adoption by Year..... 81

Table 6 Five Factors Driving Growth..... 89

Table 7 Factors Limiting Growth 94

Table 8 Key Diagnostic Laboratory Technology Trends 97

Table 9 Next Generation Sequencing Technologies – Speed and Cost 98

Table 10 - Global Market by Region 339

Table 11 Global Market by Cancer 341

Table 12 Global Market by Usage..... 347

Table 13 Global Market by Place..... 353

Table 14 Global Market by Marker..... 359

Table 15 Global Market by Product..... 365

Table 16 Breast by Country 372

Table 17 Breast by Country Price..... 373

Table 18 Breast by Country Volume..... 374

Table 19 Colorectal by Country 376

Table 20 Colorectal by Country Price..... 377

Table 21 Colorectal by Country Volume 378

Table 22 Cervical by Country 380

Table 23 Cervical by Country Price..... 381

Table 24 Cervical by Country Volume 382

Table 25 Lung by Country 384

Table 26 Lung by Country Price..... 385

Table 27 Lung by Country Volume 386

Table 28 Prostate by Country 388

Table 29 Prostate by Country Price 389

Table 30 Prostate by Country Volume 390

Table 31 Other by Country..... 392

Table 32 Other by Country Price 393

Table 33 Other by Country Volume 394

Table 34 Screening by Country 397

Table 35 Diagnostic by Country 399

Table 36 Therapy by Country..... 401

Table 37 Monitor by Country 403

Table 38 Hospital Lab by Country 406

Table 39 Lab Service by Country..... 408

Table 40 Lab Outpatient by Country 410

Table 41 Other Lab by Country 412

Table 42 Circulating Tumor Cell by Country 415

Table 43 Cell Free DNA by Country..... 417

Table 44 Vesicle by Country 419

Table 45 Other Marker by Country..... 421

Table 46 Kits by Country	424
Table 47 Instruments by Country	426
Table 48 Service by Country	428
Table 49 2022 Clinical Lab Fee Schedule	430

Table of Figures

Figure 1 Global Healthcare Spending Picture 41

Figure 2 The Global Lab Test Pie..... 42

Figure 3 The Road to Diagnostics 45

Figure 4 Comparison of Liquid vs Tissue Biopsy..... 57

Figure 5 Entities Analyzed in liquid Biopsy 59

Figure 6 Characteristics of Different Vesicle Types 73

Figure 7 The Changing Age of World Population 92

Figure 8 Health Care Consumption by Age 93

Figure 9 Cancer Incidence - Age at Diagnosis..... 93

Figure 10 Global Market Regional Share Chart 340

Figure 11 Global Market by Cancer - Base vs. Final 342

Figure 12 Global Market by Cancer Base Year 343

Figure 13 Global Market by Cancer End Year 344

Figure 14 Cancer Share by Year 345

Figure 15 Cancer Segments Growth..... 346

Figure 16 Global Market by Usage - Base vs. Final..... 348

Figure 17 Global Market by Usage Base Year..... 349

Figure 18 Global Market by Usage End Year 350

Figure 19 Usage Share by Year..... 351

Figure 20 Usage Segments Growth 352

Figure 21 Global Market by Place - Base vs. Final..... 354

Figure 22 Global Market by Place Base Year.....	355
Figure 23 Global Market by Place End Year	356
Figure 24 Place Share by Year.....	357
Figure 25 Place Segments Growth	358
Figure 26 Global Market by Marker - Base vs. Final	360
Figure 27 Global Market by Marker Base Year.....	361
Figure 28 Global Market by Marker End Year	362
Figure 29 Marker Share by Year.....	363
Figure 30 Marker Segments Growth	364
Figure 31 Global Market by Product - Base vs. Final.....	366
Figure 32 Global Market by Product Base Year	367
Figure 33 Global Market by Product End Year.....	368
Figure 34 Product Share by Year	369
Figure 35 Product Segments Growth	370
Figure 36 Breast Growth	375
Figure 37 Colorectal Diagnostics Growth	379
Figure 38 Cervical Growth	383
Figure 39 Lung Growth	387
Figure 40 Prostate Growth.....	391
Figure 41 Other Growth.....	395
Figure 42 Screening Growth	398
Figure 43 Diagnostic Growth	400
Figure 44 Therapy Growth.....	402
Figure 45 Monitor Growth.....	404

Figure 46 Hospital Lab Growth..... 407

Figure 47 Lab Service Growth..... 409

Figure 48 Lab Outpatient Growth 411

Figure 49 Other Lab Growth 413

Figure 50 Circulating Tumor Cell Growth 416

Figure 51 Cell Free DNA Growth..... 418

Figure 52 Vesicle Growth 420

Figure 53 Other Marker Growth..... 422

Figure 54 Kits Growth 425

Figure 55 Instruments Growth 427

Figure 56 Service Growth 429